Neochem Bio Solutions LimitedQ2 FY27 Results & Financial Update
Neochem Bio Solutions Limited: Q2 FY27 standalone results and company financials – revenue ₹68.92 Cr, PAT ₹7.85 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Neochem Bio Solutions price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Neochem Bio Solutions Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Neochem Bio Solutions Limited reported standalone revenue from operations of INR 68.92 crore for the half-year ended September 30, 2026, alongside other income of INR 0.37 crore, bringing total revenue to INR 69.30 crore.
Profit before tax for the period stood at INR 10.46 crore, after accounting for total expenses of INR 58.84 crore.
The company recorded a tax expense of INR 2.61 crore, leading to a net profit after tax of INR 7.85 crore for the period.
Basic and diluted earnings per share were reported at INR 4.58 each for the half-year, with the earnings note specifying that EPS figures for the half year are not annualized.
Cost of materials consumed formed the largest expense head at INR 48.52 crore, while employee benefit expenses stood at INR 4.21 crore and finance costs registered at INR 1.27 crore.
The board of directors approved the financial results during their meeting on October 27, 2026, accompanied by an unmodified limited review report from statutory auditors Patel Mehta & Associates.
01 · Business model
What does Neochem Bio Solutions do?
Neochem Bio Solutions Limited operates in the specialty chemicals sector, focusing on the development, formulation, and supply of diverse chemical products for industrial applications.
The company maintains a single operating segment structure, as the nature of its products and associated risks and returns are considered uniform under Indian Accounting Standards.
Its operational footprint involves procurement of raw materials, chemical processing and manufacturing, and commercial distribution across domestic and industrial channels.
02 · Historical context
What shaped the business before this quarter
The company was previously known as Neochem Bio Solutions Private Limited and Neochem Technologies Private Limited before its transition to a public corporate structure.
Key managerial personnel Pradip Ramniklal Solanki has been associated with the company since 2018, overseeing financial management and strategic planning prior to his re-designation.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹68.92 Cr |
| Total income | ₹69.30 Cr |
| Profit before tax | ₹10.46 Cr |
| Profit after tax | ₹7.85 Cr |
| EPS | ₹4.58 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 11.4% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 15.2% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹0.37 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations reached INR 68.92 crore for the half-year period, supported by complementary other income of INR 0.37 crore.
What drove margins
Cost of material consumed accounted for INR 48.52 crore, representing the primary input cost component influencing operating margins.
Finance costs for the period were recorded at INR 1.27 crore, reflecting debt servicing obligations relative to ongoing operational scale.
05 · Demand, customers & order book
Where demand is coming from
The company noted that one investor query was received and successfully resolved during the period, resulting in nil pending complaints as of September 30, 2026.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates within a single reporting segment, dealing in specialty chemicals where risks and returns across product lines are treated as similar.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Projects, capex and execution
Property, plant, and equipment stood at INR 30.93 crore as of September 30, 2026, alongside capital work-in-progress of INR 2.76 crore.
08 · Reported developments
What changed operationally
The company successfully recovered a substantial amount from a cyber fraud incident experienced in July 2026, with the remaining balance under active recovery assisted by legal authorities.
09 · Items worth noticing
The line items that can distort a quick read
The company recovered a substantial portion of funds lost in a cyber fraud incident from July 2026, with recovery proceedings for the remainder ongoing.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Net cash used in operating activities stood at INR 1.05 crore (INR 105.25 lakh) for the period ended September 30, 2026.
Net cash used in investing activities was reported at INR 12.96 crore (INR 1,296.35 lakh), driven primarily by purchases of fixed assets.
Net cash generated from financing activities reached INR 14.02 crore (INR 1,401.99 lakh), supported by proceeds from long-term and short-term borrowings.
Capital allocation & funding
As of September 30, 2026, the company reported long-term borrowings of INR 5.42 crore and short-term borrowings of INR 27.67 crore.
11 · Beyond the numbers
What changed beyond the numbers
Reported update
CFO Appointment
CA Harshit Shah was appointed as Chief Financial Officer and Key Managerial Personnel effective October 27, 2026, bringing over 12 years of finance and compliance experience.
Reported update
CCO Appointment
Mr. Vikram Nair was appointed as Chief Commercial Officer and Senior Management Personnel effective October 27, 2026, with over 30 years of specialty chemicals industry experience.
Reported update
Management Re-designation
Former CFO Mr. Pradip Ramniklal Solanki was re-designated to a senior management position within the company effective October 27, 2026.
12 · Key Q&A
The quarter, answered directly
What does Neochem Bio Solutions do?
Neochem Bio Solutions Limited operates in the specialty chemicals sector, focusing on the development, formulation, and supply of diverse chemical products for industrial applications.
What is the clearest takeaway from Q2 FY27?
Neochem Bio Solutions Limited reported standalone revenue from operations of INR 68.92 crore for the half-year ended September 30, 2026, alongside other income of INR 0.37 crore, bringing total revenue to INR 69.30 crore.
What drove revenue or demand?
Revenue from operations reached INR 68.92 crore for the half-year period, supported by complementary other income of INR 0.37 crore.
What mattered most for margins or profitability?
Cost of material consumed accounted for INR 48.52 crore, representing the primary input cost component influencing operating margins.
What changed operationally beyond the headline numbers?
Property, plant, and equipment stood at INR 30.93 crore as of September 30, 2026, alongside capital work-in-progress of INR 2.76 crore.
What should the next disclosure help confirm?
Monitor the progression of capital work-in-progress valued at INR 2.76 crore toward operational commissioning.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Capital Expenditure Execution: Monitor the progression of capital work-in-progress valued at INR 2.76 crore toward operational commissioning.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.